Companies › PharmaMar
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lurbinectedin Alkylating agent that binds to DNA and causes strand breaks | DCXR | Phase 3 | Leiomyosarcoma | Aug 2029 |
| PM54 | – | Phase 1 | Advanced Solid Tumor; Advanced Malignancies | Dec 2026 |
| PM534 | – | Phase 1 | Patients With Advanced Solid Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05835609 | PM534 | Phase 1 | Patients With Advanced Solid Tumors | Oncology | Oct 2026 |
| NCT05841563 | PM54 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT07644039 | PM54 | Phase 1 | Advanced Malignancies | Oncology | Apr 2029 |
| NCT06088290 | Lurbinectedin | Phase 3 | Leiomyosarcoma | Oncology | Aug 2029 |
–
RayzeBio Nuvalent Day One Biopharmaceuticals InxMed (Shanghai) SystImmune
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.